company background image
874 logo

Guangzhou Baiyunshan Pharmaceutical Holdings SEHK:874 Voorraadrapport

Laatste prijs

HK$18.06

Marktkapitalisatie

HK$47.7b

7D

-0.6%

1Y

-17.9%

Bijgewerkt

21 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

SEHK:874 Voorraadrapport

Marktkapitalisatie: HK$47.7b

874 Overzicht aandelen

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited onderzoekt, ontwikkelt, produceert en verkoopt samen met zijn dochterondernemingen Chinese patentgeneesmiddelen en westerse geneesmiddelen, chemische grondstoffen, natuurlijke en biologische geneesmiddelen en tussenproducten van chemische grondstoffen in de Volksrepubliek China en internationaal. Meer informatie

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Guangzhou Baiyunshan Pharmaceutical Holdings
Historische aandelenkoersen
Huidige aandelenkoersHK$18.06
52 Week HoogtepuntHK$24.20
52 Week LaagHK$16.62
Bèta0.59
11 maand verandering-6.04%
3 maanden verandering-6.13%
1 Jaar Verandering-17.91%
33 jaar verandering-5.54%
5 jaar verandering-25.37%
Verandering sinds IPO1,247.76%

Recent nieuws en updates

Recent updates

Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings

Nov 01
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Shareholders Have More To Worry About Than Only Soft Earnings

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models

Oct 29
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Recorded A 7.9% Miss On Revenue: Analysts Are Revisiting Their Models

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Oct 17
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital

Sep 25
Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital

Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%

Sep 04
Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%

A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Jul 15
A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down

Jun 26
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227

Jun 03
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227

The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon

May 23
The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

May 13
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?

Mar 08
Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price

Feb 23
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward

Feb 10
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward

Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?

Jan 25
Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing

Jan 09
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing

With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case

Nov 28
With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case

A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Nov 15
A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease

Oct 19
We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease

Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes

Oct 03
Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes

Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?

Aug 15
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?

Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?

Aug 02
Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?

Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall

Jul 02
Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Jun 01
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors

May 01
Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors

The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing

Mar 28
The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt

Feb 23
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt

With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case

Jan 23
With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger

Dec 24
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger

Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Nov 24
Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?

Nov 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?

Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?

Aug 02
Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year

May 30
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price

Apr 29
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt

Apr 10
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt

We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease

Jan 09
We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet

Oct 11
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet

Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Jul 12
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?

Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All

May 26
Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All

How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?

Apr 30
How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate

Apr 08
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate

These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well

Mar 25
These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 02
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain

Feb 11
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain

Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?

Jan 26
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?

Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?

Jan 06
Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?

Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet

Dec 23
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet

Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09
Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Nov 26
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Rendement voor aandeelhouders

874HK HealthcareHK Markt
7D-0.6%-0.2%1.6%
1Y-17.9%-25.8%10.1%

Rendement versus industrie: 874 overtrof de Hong Kong Healthcare industrie, die het afgelopen jaar een rendement -25.8 % opleverde.

Rendement versus markt: 874 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 10.1 % opleverde.

Prijsvolatiliteit

Is 874's price volatile compared to industry and market?
874 volatility
874 Average Weekly Movement6.2%
Healthcare Industry Average Movement7.9%
Market Average Movement8.9%
10% most volatile stocks in HK Market19.0%
10% least volatile stocks in HK Market4.3%

Stabiele aandelenkoers: 874 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van 874 is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
199728,760Hong Liwww.gybys.com.cn

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited onderzoekt, ontwikkelt, produceert en verkoopt samen met zijn dochterondernemingen Chinese patentgeneesmiddelen en westerse geneesmiddelen, chemische grondstoffen, natuurlijke en biologische geneesmiddelen en tussenproducten van chemische grondstoffen in de Volksrepubliek China en internationaal. Het bedrijf is actief via de segmenten Great Southern TCM, Great Commerce, Great Health en Overige. Het bedrijf is ook betrokken bij de groothandel, detailhandel, verkoop, import en export van westerse en Chinese geneesmiddelen, medische instrumenten, farmaceutische producten, medische apparatuur en gezondheidsproducten; en onderzoek en ontwikkeling, productie en verkoop van dranken, voedingsmiddelen, gezondheidsproducten en andere producten; en productie en verkoop van voorverpakt voedsel, zuivelproducten, enz.

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Samenvatting

Hoe verhouden de winst en inkomsten van Guangzhou Baiyunshan Pharmaceutical Holdings zich tot de beurswaarde?
874 fundamentele statistieken
MarktkapitalisatieHK$47.66b
Inkomsten(TTM)HK$3.68b
Inkomsten(TTM)HK$82.11b

8.0x

Koers/Winstverhouding

0.4x

P/S-verhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
874 resultatenrekening (TTM)
InkomstenCN¥76.39b
Kosten van inkomstenCN¥63.46b
BrutowinstCN¥12.93b
Overige uitgavenCN¥9.50b
InkomstenCN¥3.42b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)2.11
Brutomarge16.92%
Nettowinstmarge4.48%
Schuld/Eigen Vermogen Verhouding35.5%

Hoe presteerde 874 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

4.8%

Huidig dividendrendement

55%

Uitbetalingsratio